Identification | Back Directory | [Name]
1-METHYL-1H-BENZOIMIDAZOL-5-YLAMINE TRIHYDROCHLORIDE | [CAS]
10394-38-4 | [Synonyms]
NSC 240760 1-Methylbenzimidazol-5-amine 5-Amino-1-methylbenzimidazole 1-Methyl-5-aminobenzimidazole 1-Methylbenzoimidazol-5-amine 1-methyl-1H-benzimidazol-5-amine 5-Amino-1-methyl-1H-benzimidazole 5-Amino-1-methylbenzimidazole,97% 1-Methyl-1H-1,3-benzodiazol-5-aMine 1-Methyl-1H-benzo[d]iMidazol-5-aMine 1-Methyl-1H-benzo[d]iMidazol-5-YaMine 1H-Benzimidazol-5-amine,1-methyl-(9CI) 1H-Benzimidazol-5-amine, 1-methyl-, 95% 1-methyl-5-benzimidazolamine trihydrochloride 1-methyl-1H-benzimidazol-5-amine hydrochloride 1-methyl-1H-benzimidazol-5-amine(SALTDATA: FREE) 1-METHYL-1H-BENZOIMIDAZOL-5-YLAMINE TRIHYDROCHLORIDE | [Molecular Formula]
C8H12Cl3N3 | [MDL Number]
MFCD08544027 | [MOL File]
10394-38-4.mol | [Molecular Weight]
256.56 |
Chemical Properties | Back Directory | [Melting point ]
158-159 °C | [Boiling point ]
348.6±34.0 °C(Predicted) | [density ]
1.27±0.1 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Inert atmosphere,Room temperature | [form ]
Solid | [pka]
6.35±0.10(Predicted) | [Appearance]
Light brown to black Solid |
Hazard Information | Back Directory | [Uses]
1-Methyl-5-aminobenzimidazole is used in the synthesis of usnic acid derivatives as tau-aggregation and neuroinflammation inhibitor. | [Synthesis]
Example B23: 1-methyl-5-nitro-1H-benzo[d]imidazole (prepared according to the method described in WO 2005/092899; 1.14 g, 6.43 mmol) was dissolved in ethanol (50 ml) and stirred at room temperature under hydrogen (1 atm) atmosphere. 10% Pd/C catalyst (50 wt% water, 1.37 g, 0.643 mmol) was added. After 18 h of reaction, the reaction mixture was filtered through diatomaceous earth and rinsed with ethanol. The filtrates were combined and concentrated to afford the crude product 1-methyl-1H-benzo[d]imidazol-5-amine (1.02 g, 108% yield) as a dark orange oil, which was used directly in the next step of the reaction.1H NMR (400 MHz, DMSO-d6) δ 7.87 (s, 1H), 7.17 (d, J=8.4 Hz, 1H), 6.75 (d, J=2.0 Hz, 1H), 6.59 (dd, J=2.0 and 8.4 Hz, 1H), 4.73 (brs, 2H), 3.69 (s, 3H); MS (ESI) m/z: 148.0 (M+H+). Using a method similar to Example B22, 1-methyl-1H-benzo[d]imidazol-5-amine (0.50 g, 3.4 mmol), NaNO2 (0.28 g, 4.1 mmol), SnCl2-2H2O (2.8 g, 14 mmol), and 4-methyl-3-oxopentanenitrile (0.45 g, 4.1 mmol) were reacted to give the crude product 3-Isopropyl-1-(1-methyl-1H-benzo[d]imidazol-5-yl)-1H-pyrazol-5-amine (0.63 g, 73% yield), as a foam, was used directly in the next step of the reaction.1H NMR (400 MHz, DMSO-d6): δ 8.22 (s, 1H), 7.72 (dd, J=0.40 and 1.2 Hz, 1H), and 7.60 (dd, J=0.40 and 8.4 Hz, 1H), 7.42 (dd, J=2.0 and 8.4 Hz, 1H), 5.32 (s, 1H), 5.08 (brs, 2H), 3.85 (s, 3H), 2.75 (septet, J=6.8 Hz, 1H), 1.16 (d, J=6.8 Hz, 6H); MS ( ESI) m/z: 250.0 (M+H+). | [References]
[1] Patent: US2008/90856, 2008, A1. Location in patent: Page/Page column 46-47 [2] Patent: US2007/27184, 2007, A1. Location in patent: Page/Page column 20 [3] Journal of Pharmacy and Pharmacology, 1951, vol. 3, p. 420,424 [4] Gazzetta Chimica Italiana, 1955, vol. 85, p. 981,984 [5] Collection of Czechoslovak Chemical Communications, 1989, vol. 54, # 3, p. 713 - 724 |
|
|